|Podcasts|October 2, 2019

Pharm Exec Podcast Survey!

Hello all Pharm Exec podcasters! Thank you for taking the time to review our podcast survey. As you know, the podcast is about to start it’s 3rd year-and we’re really excited! We want to continue to bring you the latest and best guests this year to discuss business, strategy, R&D, and more in the pharma and biopharma industry.

Please click on the link below to complete a quick, 5-minute survey where we delve into how you listen to our episodes and what you’d most like to hear in 2020. The survey will close on November 8th, 2019.

Thank you again for your time, and we look forward to sharing more customized content in the future.

 

 

Complete the survey here!


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.